Report Sellers has added a new market research report “Angina Pectoris Drugs – Global Market Outlook (2017-23)” to its offerings.
According to Report, the Global Angina Pectoris Drugs Market is accounted for $8501.3 million in 2016 and expected to grow at a CAGR of 6.7% to reach $13441.0 million by 2023. The market factors such as sedentary lifestyle and obesity in young generation, research and developments for effective drugs, high demand for target specific and tailored drugs for angina pectoris treatment and in developing countries the awareness related to cardiovascular diseases is increasing which in turn is driving market growth. Further market will witness few trends such as introduction of new pharmacologic agents, Genomic medicines and growing trend of strategic alliances and acquisitions.
North America is projected to dominate this market due to higher prevalence of chronic diseases and better healthcare infrastructure. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. Europe is the second largest market followed by Asia Pacific. Asia Pacific is estimated to grow at significantly due to rising prevalence of angina pectoris, high awareness related to cardiovascular diseases and developing healthcare infrastructure.
The key players in global Angina Pectoris Drugs market are Astellas Pharma, Cardium Therapeutics, Cardeus Pharmaceuticals, CardioVascular BioTherapeutics (CVBT), Ark Therapeutics Group plc, HUYA Bioscience International LLC, Bristol-Myers Squibb Company, Korea Otsuka Pharmaceutical Co.,Ltd, Pfizer, Inc., Baxalta US Inc., Sanofi SA, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca PLC and TSH Biopharm
Browse through the complete description and in-depth TOC on “Global Angina Pectoris Drugs Market”
What does the Report Offers
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
Global Angina Pectoris Drugs has been segmented by drug classes covered, end users covered and regions covered
Drug Classes Covered:
Angiotensin-converting enzyme inhibitors
Beta-adrenergic blocking agents
Calcium channel blockers
Short & Long acting Nitroglycerines
End Users Covered:
Rest of Europe
Rest of Asia Pacific
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
We have a large number of reports in Healthcare Industry which can be accessed in the following link: https://www.reportsellers.com/category/healthcare-market-research-report
About Report Sellers
Report Sellers is a premium market research service provider offering market reports in varied sectors. We have a team of experienced analysts and publishers who continuously track the latest trends in different industries. Report Sellers is a brand of global repute and offers the best suited research services to its clients globally in the most satisfying manner. We have a strong network of industry experts who have successfully delivered complex research assignments in niche and top markets.
For more information, contact